Dr. Schmid on the Design and Findings of the KEYNOTE-173 Trial in TNBC

Video

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the phase Ib study of pembrolizumab (Keytruda) in combination with chemotherapy for patients with triple negative breast cancer (TNBC).

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the phase Ib study of pembrolizumab (Keytruda) in combination with chemotherapy for patients with triple negative breast cancer (TNBC).

The KEYNOTE-173 trial (NCT02622074) is a 6-cohort, phase Ib study of neoadjuvant platinum/taxane chemotherapy in combination with pembrolizumab in patients with locally advanced TNBC. The study sought to determine the safety and tolerability as well as establish a recommended phase II dose for further evaluation.

Sixty patients enrolled, with a median age of 48.5 years (26-71). Patients received 9 cycles of therapy prior to surgery, approximately 3 to 6 weeks later. To be eligible, women ≥18 years had to have a new diagnosis of locally advanced, treatment-naïve TNBC, with an ECOG score of 0 or 1, and stable organ function. Median follow-up was 19.6 months (4.0-27.4 months). At the time of data cutoff, 78.3% patients completed neoadjuvant therapy and 21.7% discontinued treatment.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute